FENC - התחייבויות לטווח ארוך להון Fennec Pharmaceuticals

Fennec Pharmaceuticals (FENC) benefits from high barriers to entry driven by stringent FDA oversight and unique patents for PEDMARK. The company's revenue is based on the sale of a hearing protection agent for children undergoing chemotherapy, which is confirmed by the price action shown on the GURU.Markets chart, where the indicator stands at 0.00. Management is currently focused on scaling the distribution of the drug across specialized oncology centers.

This ratio measures the company's reliance on long-term borrowings relative to its equity, determining financial stability and default risk during market turmoil. An analysis of the long-term debt-to-equity ratio allows for an assessment of Fennec Pharmaceuticals (FENC) and its ability to finance the complex logistics of pediatric oncology drugs without excessive credit pressure, which is critical for maintaining uninterrupted supplies to hospitals.